

haematologica *the hematology journal*

author contribution form

Title	Synergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816V
First author	Karoline V. Gleixner

According to the International Committee of Medical Journal Editors (ICMJE)

(http://www.icmje.org/ethical_1author.html):

“Authorship credit should be based on: 1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; and 3) final approval of the version to be published. Authors should meet conditions 1, 2 and 3. Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship”.

The responsible author(s) of this manuscript confirm(s) that all persons designated as authors qualify for authorship, and that each author has participated sufficiently in the work to take public responsibility for appropriate portions of the content.

Specific contributions of each author are listed on page 2 of this document.

Responsible author(s):

author(s) responsible for the integrity of the work as a whole

Name: Karoline V. Gleixner
Institute: Department of Internal Medicine I, Division of Hematology & Hemostaseology
Medical University of Vienna, Austria
e-mail: karoline.gleixner@meduniwien.ac.at

Name: Peter Valent
Institute: Department of Internal Medicine I, Division of Hematology & Hemostaseology,
Medical University of Vienna and Ludwig Boltzmann Cluster Oncology,
Vienna, Austria
e-mail: peter.valent@meduniwien.ac.at

Author contributions (maximum 1 page):

Please describe the contributions of each author, indicating who was responsible for each part of the study and the preparation of the manuscript (collection of data, experiments, data analysis, generation of figures, collection of images, interpretation of data, preparation of the text, etc.)

Karoline V. Gleixner performed Western blotting, proliferation-assays, drug combination assays, and siRNA technique and designed the study and established the research plan. Barbara Peter performed experiments involving primary neoplastic cells. Katharina Blatt performed flow cytometry experiments. Verena Suppan performed Western blotting. Emir Hadzijasufovic performed Tunel assay experiments. Deepti Radia and Andreas Reiter contributed primary bone marrow samples. Peter Valent contributed by providing logistic and budget support, and by approving the data and the final version of the manuscript.